Tarsus Pharmaceuticals (TARS) Change in Receivables (2021 - 2026)

Tarsus Pharmaceuticals' Change in Receivables history runs 6 years deep, the most recent figure standing at $30.3 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 93.33% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $52.9 million (up 62.62% YoY), while the FY2025 annual figure was $38.3 million, up 27.07% from the prior year.
• Change in Receivables for Q1 2026 stood at $30.3 million, up from $12.4 million in the prior quarter.
• The five-year high for Change in Receivables was $30.3 million in Q1 2026, with the low at -$4.1 million in Q2 2025.
• The 5-year median for Change in Receivables is $5.4 million (2023), against an average of $7.7 million.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables jumped 66329.41% in 2023, then plunged 1049.44% in 2025.
• Tarsus Pharmaceuticals' Change in Receivables stood at -$17000.0 in 2022, then surged by 66329.41% to $11.3 million in 2023, then soared by 56.33% to $17.6 million in 2024, then retreated by 29.34% to $12.4 million in 2025, then jumped by 143.52% to $30.3 million in 2026.
• Business Quant data shows TARS's Change in Receivables at $30.3 million in Q1 2026, $12.4 million in Q4 2025, and $14.3 million in Q3 2025.